Traws Pharma, a clinical-stage biopharmaceutical company, filed a U.S. IND application with the FDA for tivoxavir marboxil (TXM).
The filing represents a crucial step towards formal consideration of TXM for influenza therapy and inclusion in the national stockpile.
The Company also provided updated results from the ongoing clinical study of ratutrelvir in PAXLOVID-eligible and ineligible COVID-19 patients.
Final Step for BARDA Consideration
IND filing of tivoxavir marboxil is the final step for formal consideration by BARDA for inclusion in the strategic stockpile.
Differentiated Clinical Profile of Ratutrelvir
Updated clinical results with ratutrelvir show fewer adverse events, no viral rebounds, and a faster time to sustained symptom resolution compared to PAXLOVID.
Advantages in PAXLOVID-Ineligible Patients
Ratutrelvir's safety and efficacy advantages were confirmed in PAXLOVID-ineligible patients, providing a valuable treatment option for a significant population.
- The filing of the IND application for tivoxavir marboxil highlights Traws Pharma's commitment to developing novel therapies for respiratory viral diseases.
- The updated clinical results of ratutrelvir demonstrate its potential to address gaps in care for COVID-19 patients, especially those ineligible for existing treatments.
Traws Pharma's advancements in the development of tivoxavir marboxil and ratutrelvir showcase promising prospects in the field of influenza and COVID-19 therapies.